Search Results - "Frost, Kayla L."

Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients by Marie, Solène, Frost, Kayla L., Hau, Raymond K., Martinez-Guerrero, Lucy, Izu, Jailyn M., Myers, Cassandra M., Wright, Stephen H., Cherrington, Nathan J.

“…The liver plays a central role in the pharmacokinetics of drugs through drug metabolizing enzymes and transporters. Non-alcoholic steatohepatitis (NASH) causes…”
Get full text

Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity by Jilek, Joseph L., Frost, Kayla L., Jacobus, Kevyn A., He, Wenxi, Toth, Erica L., Goedken, Michael, Cherrington, Nathan J.

“…Disease-mediated alterations to drug disposition constitute a significant source of adverse drug reactions. Cisplatin (CDDP) elicits nephrotoxicity due to…”
Get full text

Attenuated Ochratoxin A Transporter Expression in a Mouse Model of Nonalcoholic Steatohepatitis Protects against Proximal Convoluted Tubule Toxicity by Jilek, Joseph L, Frost, Kayla L, Marie, Solène, Myers, Cassandra M, Goedken, Michael, Wright, Stephen H, Cherrington, Nathan J

“…Ochratoxin A (OTA) is an abundant mycotoxin, yet the toxicological impact of its disposition is not well studied. OTA is an organic anion transporter (OAT)…”
Get full text

Renal Transporter Alterations in Patients with Chronic Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination by Frost, Kayla L, Jilek, Joseph L, Sinari, Shripad, Klein, Robert R, Billheimer, Dean, Wright, Stephen H, Cherrington, Nathan J

“…Alterations in hepatic transporters have been identified in precirrhotic chronic liver diseases (CLDs) that result in pharmacokinetic variations causing…”
Get full text

Representative Rodent Models for Renal Transporter Alterations in Human Nonalcoholic Steatohepatitis by Frost, Kayla L, Jilek, Joseph L, Toth, Erica L, Goedken, Michael J, Wright, Stephen H, Cherrington, Nathan J

“…Alterations in renal elimination processes of glomerular filtration and active tubular secretion by renal transporters can result in adverse drug reactions…”
Get full text

Increased Renal Expression of Complement Components in Patients With Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination by Frost, Kayla L, Jilek, Joseph L, Thompson, Austin D, Klein, Robert R, Sinari, Shripad, Torabzedehkorasani, Elmira, Billheimer, Dean D, Schnellmann, Rick G, Cherrington, Nathan J

“…Abstract Inflammatory liver diseases, including nonalcoholic steatohepatitis (NASH), alcohol-associated liver disease (ALD), hepatitis C virus (HCV), and…”
Get full text

Cell Model for Studying Nucleoside Transporters, a Key Component of the Blood‐Testis Barrier by Miller, Siennah R, Morales, Mark N, Frost, Kayla L, Cherrington, Nathan J, Wright, Stephen H

“…Sertoli cells in the testis represent the principle element of the Blood‐Testis Barrier (BTB). Equilibrative nucleoside transporters (ENTs) are responsible for…”
Get full text

Mechanistic basis of increased susceptibility to nephrotoxicants in chronic liver disease by Frost, Kayla L., Marie, Solène, Cherrington, Nathan J.

“…The global prevalence of chronic liver disease (CLD) is a major public health concern due to its ability to alter the predicted pharmacokinetics of…”
Get full text